Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by RalphRalphon Jan 06, 2021 3:13pm
139 Views
Post# 32235013

RE:Somethings coming - recap

RE:Somethings coming - recap
I enjoyed the depth of your post, but why would the market cap immediately jump after the holdings company is combined? I can see a small increase, but I don't think that event is going to cause the share price to rocket. I understand that it adds an immense amount of intrinsic value to the company, but I just don't see the market responding with a huge share price appreciation.  I think that partnership is the only potentially huge catalyst in the near future.  The company needs a big Pharma partnership & the spotlight that comes with it for market validation to occur.
 
Also, I don't think Antibe Therapeutics currently owns any IP; it's all in the holding company.  They're just leasing the NSAIDS + Hydrogen Sulfide IP, I believe.
 


mstrmnd wrote: IR has been quiet

Likely seeking clarification on how to respond 

June 1, 2020 - Extremely positive topline results for Phase 2b on background of simply spectular Phase 2a results where it's quite conclusive from the sample size and power of the  2a and 2b study that Phase 3 will be a slam dunk as well!  The probability of successful Phase 3 trials are very high.  100% Antibe management knows and is trying to slowly let the information out.  It's beyond obvious after the latest press release of merger with Antibe Hold Co. that the market cap will jump overnight when combined.  The combined entity will need to meet the minimum requirements for NASDAQ in 2021 so clearly this is part of the bigger plan.  Time to partnership is becoming smaller and smaller, so the window is closing to get in for this current opportunity.     

My immediate question is what patents and IP rights are in Antibe Hold Co?  I suspect the future patent IP with hydrogen sulfide + other groups of medications is just through the roof.  Given what we currently know, it's likely north of $10B easily.  

Antibe Therapeutics = NSAIDS + Hydrogen Sulfide
Antibe Holdings = ?Cannabinoids + Hydrogen Sulfide (check the most recent ATB-352 publication)
Antibe Holdlings = ?Immunosuppressives + Hydrogen Sulfide
What else? 

Antibe is legit.  They want to progressively release the genie out of the bottle.  Keep the upside high for NASDAQ for momentum where they are aligned with the rebounding market.  I am expecting big things for Antibe this year.  

June 1, 2020 - 9:30 am EST market marker opened at $8.90  - tremendous built up selling pressure where it was known that whether $14.00 (expected - this is what Echelon themselves said) vs. $8.90 there's a clear direction what would happen.  So they jumbled the words, create some confusion, rode the wave down, decided cash in on some profits, execute an orchestrated deal with Echelon using the "markets" as an excuse to keep the MC low.  Why?  

Because they have a couple aces that are about to be played in 2021:
1. Antibe Hold Co + Antibe Therapeutics = $ x billion
2. Uplist to NASDAQ (undervalued compared to comps for Phase 3, huge upside) 
3. Antibe + Partnership = $ x billion

ATE.TO market cap is significantly discounted unnessariliy for a risk that no longer exists and now that we are in a new tax year, somethings definitely coming soon, and market cap could change overnight. 

Do your own DD.  GLTA!



<< Previous
Bullboard Posts
Next >>